Advertisement

Investigational New Drugs

, Volume 34, Issue 3, pp 394–396 | Cite as

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

  • Satomi Watanabe
  • Masayuki TakedaEmail author
  • Takayuki Takahama
  • Tsutomu Iwasa
  • Junji Tsurutani
  • Junko Tanizaki
  • Toshio Shimizu
  • Kazuko Sakai
  • Yoshitaka Wada
  • Noritaka Isogai
  • Kazuto Nishio
  • Kazuhiko Nakagawa
SHORT REPORT

Summary

Extramammary Paget’s disease is a malignant intraepithelial carcinoma, which constitutes less than 1 % of all vulvar malignancies. Surgical resection is the first treatment of choice and standard chemotherapy has not been established for advanced or recurrent disease. Experimental and clinical studies have identified human epidermal growth receptor 2 as a potential therapeutic target. A 63-year-old male was referred for recurrent extramammary Paget’s disease after surgery. Human epidermal growth receptor 2 was shown to be overexpressed and amplified by immunohistochemical analysis and fluorescence in situ hybridization analysis, respectively. After two cycles of trastuzumab monotherapy, all lymph node metastases decreased in size. However, he experienced recurrence in the lymph nodes during the seven courses of trastuzumab. As a subsequent treatment, trastuzumab was administered in combination with docetaxel and pertuzumab; clinical response was sustained for 12 months without significant adverse events.

Keywords

Extramammary Paget’s disease HER2 Molecular targeted therapy 

Notes

Acknowledgments

This study was supported in part by JSPS KAKENHI Grant Number 15 K21525, Uehara Memorial Foundation, and Takeda Science Foundation.

Authors’ contributions

SW and MT were responsible for clinical management of the patient, acquisition of data, and drafting the manuscript; TI, TT, JT, YW, NI, JT, TS, KS, KN and KN were responsible for interpretation of data and critical revision of the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Patient consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images before the patient received chemotherapy.

Conflict Interest

Kazuhiko Nakagawa received honoraria from Chugai pharmaceuticals.

References

  1. 1.
    Parker LP, Parker JR, Bodurka-Bevers D et al (2000) Paget’s disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 77:183–189CrossRefPubMedGoogle Scholar
  2. 2.
    Fanning J, Lambert HC, Hale TM et al (1999) Paget’s disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget’s disease, and recurrence after surgical excision. Am J Obstet Gynecol 180:24–27CrossRefPubMedGoogle Scholar
  3. 3.
    Tebes S, Cardosi R, Hoffman M (2002) Paget’s disease of the vulva. Am J Obstet Gynecol 187:281–283, discussion 283–284 CrossRefPubMedGoogle Scholar
  4. 4.
    Tokuda Y, Arakura F, Uhara H (2015) Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease. Int J Clin Oncol 20:194–197CrossRefPubMedGoogle Scholar
  5. 5.
    Oashi K, Tsutsumida A, Namikawa K et al (2014) Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 170:1354–1357CrossRefPubMedGoogle Scholar
  6. 6.
    Brummer O, Stegner HE, Bohmer G et al (2004) HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 95:336–340CrossRefPubMedGoogle Scholar
  7. 7.
    Richter CE, Hui P, Buza N et al (2010) HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol 63:544–547CrossRefPubMedGoogle Scholar
  8. 8.
    Barth P, Dulaimi Al-Saleem E, Edwards KW et al (2015) Metastatic extramammary Paget’s disease of scrotum responds completely to single agent Trastuzumab in a hemodialysis patient: case report molecular profiling and brief review of the literature. Case Rep Oncol Med 2015:895151PubMedPubMedCentralGoogle Scholar
  9. 9.
    Wakabayashi S, Togawa Y, Yoneyama K et al (2012) Dramatic clinical response of relapsed metastatic extramammary Paget’s disease to Trastuzumab Monotherapy. Case Rep Dermatol Med 2012:401362PubMedPubMedCentralGoogle Scholar
  10. 10.
    von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006CrossRefGoogle Scholar
  11. 11.
    Swain SM, Kim SB, Cortes J et al (2013) Pertuzumab, Trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Satomi Watanabe
    • 1
  • Masayuki Takeda
    • 1
    Email author
  • Takayuki Takahama
    • 1
  • Tsutomu Iwasa
    • 1
  • Junji Tsurutani
    • 1
  • Junko Tanizaki
    • 1
  • Toshio Shimizu
    • 1
  • Kazuko Sakai
    • 2
  • Yoshitaka Wada
    • 3
  • Noritaka Isogai
    • 3
  • Kazuto Nishio
    • 2
  • Kazuhiko Nakagawa
    • 1
  1. 1.Department of Medical OncologyKinki University Faculty of MedicineOsaka-SayamaJapan
  2. 2.Department of Genome BiologyKinki University Faculty of MedicineOsaka-SayamaJapan
  3. 3.Department of Plastic and Reconstructive SurgeryKinki University Faculty of MedicineOsaka-SayamaJapan

Personalised recommendations